Should I Buy TBPH? TBPH 2026 Analysis

Should You Buy Theravance Biopharma Inc (TBPH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

19.180

1 Day change

0.79%

52 Week Range

21.030

Analysis Updated At

2026/01/26

Theravance Biopharma Inc (TBPH) is not a strong buy for a beginner, long-term investor at this moment. While the stock has positive technical indicators and bullish price targets from analysts, insider selling, declining financial metrics, and lack of significant catalysts suggest caution. The investor's funds may be better allocated elsewhere for long-term growth.

Technical Analysis

The MACD is above 0 and positively contracting, indicating a potential upward trend. RSI is neutral at 56.621, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 20.865), which could limit immediate upside potential.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have raised price targets significantly, with BTIG increasing the target to $40 and H.C. Wainwright raising it to $20, both maintaining Buy ratings. Revenue increased by 18.51% YoY in Q3 2025.

Neutral/Negative Catalysts

Insider selling has increased by 411.55% over the last month, signaling potential lack of confidence. Net income and EPS have dropped significantly YoY (-128.47% and -126.92%, respectively). No recent congress trading data or significant news catalysts for the stock.

Financial Performance

In Q3 2025, revenue grew by 18.51% YoY to $19.99M, but net income dropped by -128.47% YoY to $3.62M, and EPS declined by -126.92% YoY to $0.07. Gross margin remained stable at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are optimistic, with BTIG raising the price target to $40 and H.C. Wainwright increasing it to $20. Both firms maintain Buy ratings, citing strong sales of Yupelri and adjustments for rare disease launches.

5 Analyst Rating

Wall Street analysts forecast TBPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TBPH is 28.4 USD with a low forecast of 13 USD and a high forecast of 42 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 19.030

Low

Averages

28.4

High

Current: 19.030

Low

Averages

28.4

High

BTIG

Buy

upgrade

$25 -> $40

AI Analysis

2025-11-26

Reason

BTIG

Price Target

$25 -> $40

AI Analysis

2025-11-26

upgrade

Buy

Reason

BTIG raised the firm's price target on Theravance Biopharma to $40 from $25 and keeps a Buy rating on the shares. The firm is revisiting its annualized net price for ampreloxetine in nOH and lowering standalone operating expense assumptions to better reflect a rare disease launch, the analyst tells investors in a research note.

H.C. Wainwright

Douglas Tsao

Buy

maintain

$15 -> $20

2025-11-11

Reason

H.C. Wainwright

Douglas Tsao

Price Target

$15 -> $20

2025-11-11

maintain

Buy

Reason

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Theravance Biopharma to $20 from $15 and keeps a Buy rating on the shares following the Q3 report. Net sales of Yupelri reached an all-time high of $71.4M, the analyst tells investors in a research note. The firm upped estimates for 2026 and beyond.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TBPH

Unlock Now

TBPH Should I Buy

TBPH Should I Buy

Should You Buy Theravance Biopharma Inc (TBPH) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch